Text Size

Establishment and Characterization of Patient-Derived Non-Small Cell Lung Cancer Xenografts and Cell Cultures

The recruitment status of this study is unknown because the information has not been verified recently.
Verified May 2010 by National University Hospital, Singapore.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
National University Hospital, Singapore
ClinicalTrials.gov Identifier:
NCT01130571
First received: May 24, 2010
Last updated: May 25, 2010
Last verified: May 2010
History of Changes
  Purpose

Xenografts and cell cultures provide sufficient material for analyses at the protein, RNA and DNA level. Patient derived NSCLC xenografts and cell lines are available but none however are Asian in origin. Given the emerging evidence to suggest inter-ethnic differences in NSCLC biology, new models of preclinical drug evaluation should be designed and validated using Asian tumors. Furthermore, such models will allow studies of biological mechanisms of sensitivity and/or resistance and also the study of dynamic regulations under standardized conditions in the Asian context.


Condition Intervention
Non Small Cell Lung Cancer
 Procedure: Xenografts and cell cultures

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective

Resource links provided by NLM:

MedlinePlus related topics: Cancer Lung Cancer
U.S. FDA Resources

Further study details as provided by National University Hospital, Singapore:

Groups/Cohorts Assigned Interventions
Non-Small Cell Lung Cancer Procedure: Xenografts and cell cultures

  Eligibility

Ages Eligible for Study:   21 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

The investigators for this protocol are clinicians and scientists in the departments of Cardiac/Thoracic and Vascular Surgery, Haematology and Oncology, Pathology, Radiation Oncology, Respiratory Medicine and the Cancer Sciences Institute of Singapore (CSIS) from NUH and NUS with major roles in their departments in the clinical management and/or research of lung cancer. Each will be providing access to clinical information and assisting in the collection and processing of samples, according to their resources and expertise.

Criteria

Inclusion Criteria:

  • Patients aged 21 years and above.
  • Undergoing a surgical resection of tumor as part of clinical management

Exclusion Criteria:

  • Patient or legally acceptable representative unable to provide consent patient in the judgement of the study investigator, is medically unsuitable for this study
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01130571

Contacts
Contact: Ross Andrew Soo, MBBS 65 3772 4624 ross_soo@nuhs.edu.sg

Locations
Singapore
National University Hospital Recruiting
Singapore, Singapore
Contact: Ross Andrew Soo, MBBS     65 6772 4624     ross_soo@nuhs.edu.sg    
Principal Investigator: Ross Andrew Soo, MBBS            
Sponsors and Collaborators
National University Hospital, Singapore
  More Information

Publications:

ClinicalTrials.gov Identifier: NCT01130571     History of Changes
Other Study ID Numbers: NS03/05/09
Study First Received: May 24, 2010
Last Updated: May 25, 2010
Health Authority: Singapore: Domain Specific Review Boards

Additional relevant MeSH terms:
Carcinoma, Non-Small-Cell Lung
Lung Neoplasms
Carcinoma, Bronchogenic
Bronchial Neoplasms
Respiratory Tract Neoplasms
 Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases

ClinicalTrials.gov processed this record on May 19, 2013